Sal Braico’s Post

Exciting news in colorectal cancer (CRC) screening! 🩸🧬 The FDA approved Guardant Health's Shield blood test for adults 45+ with average risk of CRC. Key points: - Meets Medicare coverage requirement but is not yet covered by any other insurers - Self-pay price: $895 - 83% effective in identifying colon cancer with 90% specificity for advanced neoplasia (20,000-patient NEJM study) - Only 13% sensitivity for polyp detection While colonoscopies and fecal tests like Exact Sciences' Cologuard remain standard, Shield offers a simple blood test alternative. This should boost screening rates—crucial as colon cancer incidence rises, particularly among younger individuals. In 2023, the American Cancer Society reported that 20% of CRC diagnoses in 2019 were in patients younger than 55. In 1995, it was only 10%! #HealthcareTech #Cancer #MedicalInnovation #Shield https://lnkd.in/gWQz7zJE

Guardant's blood-based cancer test moves closer to Medicare coverage with FDA approval

Guardant's blood-based cancer test moves closer to Medicare coverage with FDA approval

reuters.com

To view or add a comment, sign in

Explore topics